Cargando…

New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab: A case report

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, they may cause immune-related adverse events. Although there have been a few reports of new-onset type 1 diabetes mellitus (T1DM) during ICI treatment, T1DM as a delayed immune-related event after discontinuing immuno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seo, Je Hyun, Lim, Taekyu, Ham, Ahrong, Kim, Ye An, Lee, Miji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439731/ https://www.ncbi.nlm.nih.gov/pubmed/36107574 http://dx.doi.org/10.1097/MD.0000000000030456

Ejemplares similares

Intrahepatic cholangiocarcinoma initially diagnosed as adenocarcinoma of unknown primary with hepatoduodenal ligament lymph node metastases: A case report
por: Noh, Sangik, et al.
Publicado: (2023)

Real-World Outcomes of Nivolumab, Pembrolizumab, and Atezolizumab Treatment Efficacy in Korean Veterans with Stage IV Non-Small-Cell Lung Cancer
por: Ham, Ahrong, et al.
Publicado: (2023)

Two cases of delayed onset of immune‐related adverse events after discontinuation of nivolumab in patients with metastatic renal cell cancer
por: Nakai, Yasutomo, et al.
Publicado: (2021)

Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
por: Bae, Heewon, et al.
Publicado: (2023)

Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab
por: Olsen, Eric, et al.
Publicado: (2023)

Immune checkpoint inhibitor-induced diabetes mellitus with nivolumab
por: Zand Irani, Anis, et al.
Publicado: (2023)

New-Onset Type 1 Diabetes Mellitus After Treatment With Nivolumab for Melanoma
por: Baroud, Sarah, et al.
Publicado: (2021)

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
por: Tan, Irena, et al.
Publicado: (2018)

Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report
por: Antoniou, Sofia, et al.
Publicado: (2021)

SAT-673 Acute Onset Type 1 Diabetes Mellitus Caused by the Checkpoint Inhibitor Nivolumab
por: Ansari, Mohammad Jamal Uddin, et al.
Publicado: (2020)

Delayed treatment-free response after romiplostim discontinuation in pediatric chronic immune thrombocytopenia
por: Lim, Hyun Ji, et al.
Publicado: (2020)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Acute‐onset type 1 diabetes mellitus caused by nivolumab in a patient with advanced pulmonary adenocarcinoma
por: Kumagai, Ryo, et al.
Publicado: (2017)

Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab
por: Sawada, Ryo, et al.
Publicado: (2021)

Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report
por: Arigami, Takaaki, et al.
Publicado: (2020)

New-onset insulin-dependent diabetes due to nivolumab
por: Zaied, Ali A, et al.
Publicado: (2018)

Rapid-onset diabetic ketoacidosis secondary to nivolumab therapy
por: Lee, Senhong, et al.
Publicado: (2018)

Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance
por: Couey, Marcus A., et al.
Publicado: (2019)

P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
por: Fedorova, Liudmila, et al.
Publicado: (2022)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
por: Zhou, Shi, et al.
Publicado: (2019)

Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
por: Nakajima, Nobuyuki, et al.
Publicado: (2020)

A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient
por: Yatsuda, Yukino, et al.
Publicado: (2020)

Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case report
por: Boswell, Laura, et al.
Publicado: (2021)

Late‐onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancer
por: Ichihara, Seiya, et al.
Publicado: (2022)

The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma
por: Yazaki, Tomotaka, et al.
Publicado: (2021)

Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports
por: Zezza, Marco, et al.
Publicado: (2019)

Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study
por: Fink, Morten, et al.
Publicado: (2021)

Early Discontinuation and Restart of Insulin in the Treatment of Type 2 Diabetes Mellitus
por: Ascher-Svanum, Haya, et al.
Publicado: (2014)

Re: Long-term control in a patient with metastatic lung adenocarcinoma after discontinuation of nivolumab
por: Pampín-Sánchez, R, et al.
Publicado: (2021)

Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer
por: Higashi, Tetsuo, et al.
Publicado: (2020)

Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
por: Les, Iñigo, et al.
Publicado: (2021)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018)

Nivolumab-induced autoimmune diabetes mellitus and hypothyroidism in a patient with rectal neuroendocrine tumor
por: Haque, Waqas, et al.
Publicado: (2020)

Nivolumab-induced diabetes mellitus—a case report with literature review of the treatment options
por: Daetwyler, Eveline, et al.
Publicado: (2023)

Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
por: Godwin, James Luke, et al.
Publicado: (2017)

Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report
por: Tanaka, Takeshi, et al.
Publicado: (2022)

Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events
por: Imafuku, Keisuke, et al.
Publicado: (2017)

Rare Adverse Events Related to Nivolumab, an Immune Checkpoint Inhibitor: A Case Series
por: Ganta, Nagapratap, et al.
Publicado: (2022)

Immune-related adverse events and prognosis in patients with upper gastrointestinal cancer treated with nivolumab
por: Hara, Yoshihiro, et al.
Publicado: (2022)

Nivolumab and immune‐mediated colitis
por: Walker, Heather, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3lmoqfi4kirboojijf1rmlptsi